Rxsight Inc - Understand $rxst stock

$RXST Market Cap: $2.228 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$115.2M

TTM

Gross Margin

65.81%

TTM

Net Earnings

-$36.77M

TTM

Current Assets

$281.2M

Q2 2024

Current Liabilities

$19.62M

Q2 2024

Current Ratio

1433.49%

Q2 2024

Total Assets

$305.5M

Q2 2024

Total Liabilities

$30.29M

Q2 2024

Book Value

$275.2M

Q2 2024

Cash

$24.45M

Q2 2024

P/E

-60.59

Sep 17, 2024 EST

Free Cash Flow

-$35.35M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019
Revenue	$89.08M	$49.01M	$22.59M	$14.68M	$2.241M
YoY Change	81.77%	116.9%	53.92%	554.98%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019
Revenue	$89.08M	$49.01M	$22.59M	$14.68M	$2.241M
Cost Of Revenue	$35.31M	$27.68M	$18.08M	$12.97M	$4.060M
Gross Profit	$53.77M	$21.33M	$4.517M	$1.705M	-$1.819M
Gross Profit Margin	60.36%	43.52%	19.99%	11.62%	-81.17%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019
Selling, General & Admin	$74.80M	$58.67M	$32.81M	$15.18M	$15.18M
YoY Change	27.5%	78.83%	116.16%	-0.01%
% of Gross Profit	139.12%	275.06%	726.26%	890.09%
Research & Development	$29.05M	$25.98M	$24.50M	$21.93M	$29.42M
YoY Change	11.82%	6.05%	11.69%	-25.45%
% of Gross Profit	54.03%	121.82%	542.37%	1286.45%
Depreciation & Amortization	$4.078M	$3.884M	$3.975M	$3.853M	$3.930M
YoY Change	4.99%	-2.29%	3.17%	-1.96%
% of Gross Profit	7.58%	18.21%	88.0%	225.98%
Operating Expenses	$103.9M	$84.65M	$57.30M	$37.12M	$44.77M
YoY Change	22.69%	47.71%	54.39%	-17.1%
Operating Profit	-$50.09M	-$63.32M	-$52.79M	-$35.41M	-$46.59M
YoY Change	-20.9%	19.95%	49.07%	-23.99%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019
Interest Expense	$3.308M	$4.946M	$3.682M	$510.0K	$2.281M
YoY Change	-33.12%	34.33%	621.96%	-77.64%
% of Operating Profit
Other Income/Expense, Net		$0.00	$7.735M	$63.01M	$170.0M
YoY Change		-100.0%	-87.72%	-62.94%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019
Pretax Income	-$48.59M	-$66.75M	-$48.68M	$27.63M	$126.2M
YoY Change	-27.21%	37.11%	-276.17%	-78.11%
Income Tax	$20.00K	$9.000K	$8.000K	$57.00K	$24.00K
% Of Pretax Income				0.21%	0.02%
Net Earnings	-$48.61M	-$66.76M	-$48.69M	$27.58M	$126.2M
YoY Change	-27.19%	37.11%	-276.57%	-78.15%
Net Earnings / Revenue	-54.57%	-136.22%	-215.5%	187.87%	5632.31%
Basic Earnings Per Share	-$1.41	-$2.41	-$3.57	$0.91
Diluted Earnings Per Share	-$1.41	-$2.41	-$3.57	$0.15	$4.800M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019
Cash & Short-Term Investments	$127.2M	$105.8M	$159.3M	$68.98M	$80.67M
YoY Change	20.21%	-33.6%	131.0%	-14.5%
Cash & Equivalents	$9.692M	$11.83M	$24.36M	$13.99M	$7.958M
Short-Term Investments	$117.5M	$93.97M	$135.0M	$54.98M	$72.71M
Other Short-Term Assets	$3.523M	$2.962M	$4.069M	$1.372M	$1.523M
YoY Change	18.94%	-27.21%	196.57%	-9.91%
Inventory	$17.42M	$14.84M	$8.032M	$8.288M	$7.219M
Prepaid Expenses
Receivables	$20.28M	$10.96M	$4.862M	$2.865M	$789.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$168.4M	$134.6M	$176.3M	$81.50M	$90.20M
YoY Change	25.16%	-23.68%	116.31%	-9.64%
Property, Plant & Equipment	$13.29M	$14.08M	$15.50M	$18.61M	$19.25M
YoY Change	-5.65%	-9.16%	-16.69%	-3.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$858.0K	$1.528M	$925.0K	$571.0K	$983.0K
YoY Change	-43.85%	65.19%	62.0%	-41.91%
Total Long-Term Assets	$14.14M	$15.61M	$16.43M	$19.18M	$20.23M
YoY Change	-9.39%	-4.97%	-14.35%	-5.22%
Total Assets	$182.6M	$150.2M	$192.7M	$100.7M	$110.4M
YoY Change
Accounts Payable	$3.863M	$2.595M	$1.689M	$1.134M	$2.199M
YoY Change	48.86%	53.64%	48.94%	-48.43%
Accrued Expenses	$12.40M	$10.81M	$8.615M	$4.935M	$5.715M
YoY Change	14.72%	25.48%	74.57%	-13.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$37.00K	$152.0K	$20.00K	$27.00K	$129.0K
YoY Change	-75.66%	660.0%	-25.93%	-79.07%
Total Short-Term Liabilities	$20.90M	$17.24M	$11.08M	$11.60M	$8.457M
YoY Change	21.27%	55.61%	-4.51%	37.16%
Long-Term Debt	$118.0K	$40.21M	$39.78M	$24.44M	$54.00K
YoY Change	-99.71%	1.09%	62.78%	45151.85%
Other Long-Term Liabilities	$1.167M	$2.813M	$3.625M	$8.870M	$78.95M
YoY Change	-58.51%	-22.4%	-59.13%	-88.77%
Total Long-Term Liabilities	$1.285M	$43.03M	$43.40M	$33.31M	$79.01M
YoY Change	-97.01%	-0.87%	30.31%	-57.84%
Total Liabilities	$22.19M	$60.26M	$54.48M	$44.91M	$87.46M
YoY Change	-63.18%	10.62%	21.32%	-48.66%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	34.46M	27.66M	13.63M	3.707M
Diluted Shares Outstanding	34.46M	27.66M	13.63M	5.532M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $2.2278 Billion

About Rxsight Inc

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 374 full-time employees. The company went IPO on 2021-07-30. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. The company designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.

Industry: Ophthalmic Goods Peers: Bioventus Inc Cerus Corp Sanara Medtech Inc OraSure Technologies Inc Pulmonx Corp VolitionRX Ltd SmileDirectClub Inc TELA Bio Inc Utah Medical Products Inc